{'fraction_non_alphanumeric': 0.01644100580270793, 'fraction_numerical': 0.0, 'mean_word_length': 5.946308724832215, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Brucella canis: An update on research and clinical management.

In Canada, Brucella canis remains a potentially devastating infectious agent that is still considered uncommon, despite the increasing international movement of dogs. There may be a growing risk to the Canadian canine population due to a reliance on outdated seroprevalence studies and the lack of federal regulation. With the complex diagnostic and management challenges associated with Brucella canis, a One Health approach is necessary to address the need for ongoing research, including updating canine and human seroprevalence rates in Canada, elucidating the pathogenesis, and determining the most appropriate treatment and prevention strategies. Clinical management decisions are often complicated by currently available treatment protocols, and health risks to both canine and human populations. This article integrates recent research focusing on the pathogenesis, diagnosis, and treatment of Brucella canis, and outlines current clinical management approaches.